600594 益佰制药
已收盘 05-07 15:00:00
资讯
新帖
简况
每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会
证券之星 · 05-02
每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会
益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%
证券之星 · 04-30
益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%
每周股票复盘:益佰制药(600594)一季度净利亏损2952万
证券之星 · 04-26
每周股票复盘:益佰制药(600594)一季度净利亏损2952万
益佰制药(600594)2026年一季报简析:净利润同比下降214.57%
证券之星 · 04-24
益佰制药(600594)2026年一季报简析:净利润同比下降214.57%
图解益佰制药年报:第四季度单季净利润同比下降64.12%
证券之星 · 04-23
图解益佰制药年报:第四季度单季净利润同比下降64.12%
异动快报:益佰制药(600594)4月21日9点33分触及涨停板
证券之星 · 04-21
异动快报:益佰制药(600594)4月21日9点33分触及涨停板
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
证券之星 · 04-19
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
异动快报:益佰制药(600594)4月15日14点52分触及涨停板
证券之星 · 04-15
异动快报:益佰制药(600594)4月15日14点52分触及涨停板
4月13日益佰制药(600594)龙虎榜数据
证券之星 · 04-13
4月13日益佰制药(600594)龙虎榜数据
每周股票复盘:益佰制药(600594)近5日4次登龙虎榜
证券之星 · 04-12
每周股票复盘:益佰制药(600594)近5日4次登龙虎榜
4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动
证券之星 · 04-09
4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动
股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元
证券之星 · 04-09
股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元
4月7日益佰制药(600594)龙虎榜数据
证券之星 · 04-07
4月7日益佰制药(600594)龙虎榜数据
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
证券之星 · 04-05
每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜
益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%
中金财经 · 04-03
益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%
BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?
格隆汇 · 04-02
BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?
异动快报:益佰制药(600594)4月2日10点28分触及涨停板
证券之星 · 04-02
异动快报:益佰制药(600594)4月2日10点28分触及涨停板
4月1日益佰制药(600594)龙虎榜数据
证券之星 · 04-01
4月1日益佰制药(600594)龙虎榜数据
益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%
证券之星 · 03-30
益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%
益佰制药最新公告:获得注射用阿扎胞苷药品注册证书
证券之星 · 03-27
益佰制药最新公告:获得注射用阿扎胞苷药品注册证书
加载更多
公司概况
公司名称:
贵州益佰制药股份有限公司
所属行业:
医药制造业
上市日期:
2004-03-23
主营业务:
贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售,综合性医院、肿瘤专科医院、肿瘤放疗中心的运营与管理,开发、研制、生产及销售以苗药为特色的大健康产品。公司的主要产品是注射用洛铂、银杏达莫注射液、抗肿瘤类、心脑血管类、男科类、妇科类、其他、注射用瑞替普酶、科博肽、医疗服务、糖果、植物饮料、膏滋。
发行价格:
14.40
{"stockData":{"symbol":"600594","market":"SH","secType":"STK","nameCN":"益佰制药","latestPrice":4.07,"timestamp":1778137200000,"preClose":4.07,"halted":0,"volume":32498550,"delay":0,"changeRate":0,"floatShares":792000000,"shares":792000000,"eps":-0.4416,"marketStatus":"已收盘","change":0,"latestTime":"05-07 15:00:00","open":4.06,"high":4.09,"low":4.03,"amount":132000000,"amplitude":0.0147,"askPrice":4.07,"askSize":10671,"bidPrice":4.06,"bidSize":17827,"shortable":0,"etf":0,"ttmEps":-0.4416,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.07,"symbolType":"stock","openAndCloseTimeList":[[1778117400000,1778124600000],[1778130000000,1778137200000]],"highLimit":4.48,"lowLimit":3.66,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":791927400,"isCdr":false,"pbRate":1.49,"roa":"--","roe":"--","epsLYR":-0.42,"committee":0.229118,"marketValue":3223000000,"turnoverRate":0.041,"status":2,"floatMarketCap":3223000000},"requestUrl":"/m/hq/s/600594","defaultTab":"news","newsList":[{"id":"2632977623","title":"每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2632977623","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632977623?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:09","pubTimestamp":1777673360,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,益佰制药报收于4.05元,较上周的4.33元下跌6.47%。本周关注点公司公告汇总:贵州益佰制药将于2026年5月11日举行2025年度业绩说明会,管理层将与投资者在线交流。公司公告汇总:益佰制药召开2025年年度股东会,审议利润分配预案、董事薪酬方案等多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600594","BK0060","BK0096","BK0012","BK0239","BK0097","BK0188","BK0070","BK0039","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631720655","title":"益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631720655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631720655?lang=zh_cn&edition=full","pubTime":"2026-04-30 22:13","pubTimestamp":1777558399,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,益佰制药报收于4.05元,较前一交易日下跌1.7%,最新总市值为32.07亿元。近日,贵州益佰制药股份有限公司发布《关于参加“2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会”的公告》。投资者可于公告发布日至2026年5月8日12:00前通过“贵州资本市场”微信公众号提交问题。公司已于2026年4月23日披露2025年年度报告,本次说明会将就财务状况、经营成果等与投资者交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000068743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0096","BK0070","BK0077","BK0039","BK0239","BK0012","600594","BK0060","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630680172","title":"每周股票复盘:益佰制药(600594)一季度净利亏损2952万","url":"https://stock-news.laohu8.com/highlight/detail?id=2630680172","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630680172?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:56","pubTimestamp":1777143370,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,益佰制药报收于4.33元,较上周的4.5元下跌3.78%。本周,益佰制药4月21日盘中最高价报5.04元。本周关注点来自业绩披露要点:益佰制药2026年一季报显示归母净利润-2952.49万元,同比下降214.57%。股本股东变化股东户数变动截至2026年3月31日,益佰制药股东户数为4.59万户,较2025年12月31日减少2914户,减幅5.97%。贵州益佰制药股份有限公司关于2025年年度利润分配预案公告公司2025年度拟不进行利润分配,亦不进行资本公积金转增股本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","600594","BK0060","BK0077","BK0070","BK0097","BK0012","BK0039","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629847094","title":"益佰制药(600594)2026年一季报简析:净利润同比下降214.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629847094","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629847094?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:11","pubTimestamp":1777039865,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期益佰制药发布2026年一季报。根据财报显示,益佰制药净利润同比下降214.57%。截至本报告期末,公司营业总收入3.59亿元,同比下降28.44%,归母净利润-2952.49万元,同比下降214.57%。本次财报公布的各项数据指标表现不尽如人意。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400064627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629802960","title":"图解益佰制药年报:第四季度单季净利润同比下降64.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629802960","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629802960?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:03","pubTimestamp":1776877402,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药2025年年报显示,当年度公司主营收入18.63亿元,同比下降14.31%;归母净利润-3.3亿元,同比下降3.89%;扣非净利润-3.25亿元,同比下降0.59%;其中2025年第四季度,公司单季度主营收入4.16亿元,同比下降9.56%;单季度归母净利润-2.43亿元,同比下降64.12%;单季度扣非净利润-2.41亿元,同比下降67.65%;负债率34.03%,投资收益-21.46万元,财务费用2071.58万元,毛利率59.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300002111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629035687","title":"异动快报:益佰制药(600594)4月21日9点33分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2629035687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629035687?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:35","pubTimestamp":1776735349,"startTime":"0","endTime":"0","summary":"证券之星4月21日盘中消息,9点33分益佰制药(600594)触及涨停板。其所属行业中药目前上涨。领涨股为康惠股份。该股为中药,医药,民营医院概念热股,当日中药概念上涨0.5%,医药概念上涨0.2%。4月20日的资金流向数据方面,主力资金净流入1096.19万元,占总成交额2.93%,游资资金净流入396.46万元,占总成交额1.06%,散户资金净流出1492.64万元,占总成交额4.0%。近5日资金流向一览见下表:益佰制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100016655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0096","BK0012","BK0077","600594","BK0097","BK0188","BK0039","BK0060","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628075657","title":"每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628075657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628075657?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:33","pubTimestamp":1776533587,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,益佰制药报收于4.5元,较上周的4.81元下跌6.44%。本周,益佰制药4月16日盘中最高价报4.93元。4月14日盘中最低价报4.22元。本周共计1次涨停收盘,无跌停收盘情况。益佰制药当前最新总市值35.64亿元,在中药板块市值排名52/66,在两市A股市值排名4267/5198。本周关注点交易信息汇总:益佰制药因日收盘价格跌幅偏离值达7%连续5日内第3次登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0096","BK0060","BK0012","BK0028","BK0077","BK0097","BK0188","BK0239","600594","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406102","title":"异动快报:益佰制药(600594)4月15日14点52分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627406102?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:55","pubTimestamp":1776236123,"startTime":"0","endTime":"0","summary":"证券之星4月15日盘中消息,14点52分益佰制药触及涨停板。其所属行业中药目前上涨。领涨股为康恩贝。该股为中药,医药,民营医院概念热股,当日中药概念上涨2.14%,医药概念上涨1.81%,民营医院概念上涨0.4%。4月14日的资金流向数据方面,主力资金净流出1515.31万元,占总成交额3.81%,游资资金净流出844.29万元,占总成交额2.12%,散户资金净流入2359.6万元,占总成交额5.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500021799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0060","BK0188","600594","BK0077","BK0012","BK0096","BK0039","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627436971","title":"4月13日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2627436971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627436971?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:14","pubTimestamp":1776071651,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月13日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2026年4月13日收盘,益佰制药报收于4.42元,下跌8.11%,换手率15.36%,成交量121.66万手,成交额5.44亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300022341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","600594","BK0239","BK0012","BK0096","BK0060","BK0188","BK0028","BK0070","BK0077","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626124175","title":"每周股票复盘:益佰制药(600594)近5日4次登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626124175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626124175?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:09","pubTimestamp":1775927349,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,益佰制药报收于4.81元,较上周的4.7元上涨2.34%。本周,益佰制药4月7日盘中最高价报5.11元。益佰制药当前最新总市值38.09亿元,在中药板块市值排名51/67,在两市A股市值排名4099/5196。沪深交易所2026年4月7日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券,有价格涨跌幅限制的日换手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600594","BK0096","BK0239","BK0039","BK0012","BK0070","BK0077","BK0188","BK0097","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901038","title":"4月9日益佰制药(600594)涨停分析:新药获批、成本优化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901038","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626901038?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:35","pubTimestamp":1775720140,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药4月9日涨停收盘,收盘价5.06元。今日益佰制药涨停的可能因素有:注射用阿扎胞苷获批药品注册证书,视同通过一致性评价,加速上市并拓展血液肿瘤治疗领域;产品管线丰富化增强抗风险能力;成本费用同比下降18%,经营效率改善;叠加中药Ⅱ板块联动及近期连续获龙虎榜曝光,市场关注度提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900019355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0012","BK0070","BK0077","BK0097","BK0028","BK0096","BK0039","BK0239","BK0188","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626261779","title":"股市必读:益佰制药(600594)4月8日收盘跌8.18%,主力净流出701.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626261779","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626261779?lang=zh_cn&edition=full","pubTime":"2026-04-09 01:16","pubTimestamp":1775668571,"startTime":"0","endTime":"0","summary":"截至2026年4月8日收盘,益佰制药报收于4.6元,下跌8.18%,换手率17.87%,成交量141.55万手,成交额6.61亿元。来自龙虎榜上榜:益佰制药因日收盘价格跌幅偏离值达7%连续5个交易日登榜,市场波动加剧。交易信息汇总股价提醒4月8日益佰制药收盘报4.6元,跌8.18%,当日成交1.42亿元。资金流向4月8日主力资金净流出701.79万元,占总成交额1.06%;游资资金净流出833.48万元,占总成交额1.26%;散户资金净流入1535.27万元,占总成交额2.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900001056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0077","BK0060","600594","BK0239","BK0096","BK0188","BK0039","BK0070","BK0028","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625166936","title":"4月7日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625166936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625166936?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:14","pubTimestamp":1775553284,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月7日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券,有价格涨跌幅限制的日换手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。截至2026年4月7日收盘,益佰制药报收于5.01元,上涨6.6%,换手率23.86%,成交量188.94万手,成交额8.97亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0096","BK0012","BK0028","BK0077","BK0039","BK0097","BK0188","BK0239","BK0070","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625159086","title":"每周股票复盘:益佰制药(600594)近5日3次登上龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625159086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625159086?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:07","pubTimestamp":1775322431,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,益佰制药报收于4.7元,较上周的3.84元上涨22.4%。本周,益佰制药4月3日盘中最高价报5.27元,股价触及近一年最高点。本周关注点交易信息汇总:益佰制药近5个交易日内第3次因日换手率达20%等情形登上龙虎榜。沪深交易所2026年4月2日公布的交易公开信息显示,益佰制药因日收盘价格涨幅偏离值达到7%及连续三个交易日内累计偏离值达20%的情形登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600594","BK0097","BK0096","BK0012","BK0070","BK0039","BK0239","BK0060","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656402","title":"益佰制药(600594)披露股票交易异常波动公告,4月3日股价下跌2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656402","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624656402?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:12","pubTimestamp":1775207523,"startTime":"0","endTime":"0","summary":"贵州益佰制药股份有限公司于2026年4月3日发布《股票交易异常波动的公告》。公告显示,公司股票于2026年3月31日至4月2日连续三个交易日内日收盘价格涨幅偏离值累计超过20%,构成股票交易异常波动。公司自查并问询控股股东及实际控制人,确认不存在应披露而未披露的重大信息。董事会确认无应披露未披露事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32124840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0077","BK0039","BK0070","BK0097","BK0239","BK0060","BK0012","BK0028","BK0096","BK0188","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157850","title":"BD+业绩双重炸裂,创新药多股涨停,黄金窗口期来了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157850?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:03","pubTimestamp":1775109822,"startTime":"0","endTime":"0","summary":"进入收获期","market":"hk","thumbnail":"https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4283048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["PALL","DZZ","02186","BK1191","DGP","06978","02162","DUST","SGCmain","UGL","GDXJ","IAUI","JNUG","XME","GCmain","QOmain","600488","NUGT","IAU","000950","JDST","300086","GLL","IAUM","GDXD","SGUmain","159934","BK0188","BTGD","SGOL","600594","USG","GLD","BK4585","OUNZ","GDXU","AAAU","159831","GLTR","000788","MGCmain","GDXY","GLDM","GDX","159992","PHYS","603222","CEF","1OZmain","518880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624852188","title":"异动快报:益佰制药(600594)4月2日10点28分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2624852188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624852188?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:35","pubTimestamp":1775097323,"startTime":"0","endTime":"0","summary":"证券之星4月2日盘中消息,10点28分益佰制药(600594)触及涨停板。其所属行业中药目前上涨。领涨股为益佰制药。该股为中药,医药,民营医院概念热股,当日中药概念上涨0.54%,医药概念上涨0.3%。4月1日的资金流向数据方面,主力资金净流入9361.38万元,占总成交额23.56%,游资资金净流出4223.56万元,占总成交额10.63%,散户资金净流出5137.82万元,占总成交额12.93%。近5日资金流向一览见下表:益佰制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200011187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0039","600594","BK0239","BK0097","BK0188","BK0077","BK0060","BK0028","BK0012","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599429","title":"4月1日益佰制药(600594)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599429?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:20","pubTimestamp":1775035225,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月1日公布的交易公开信息显示,益佰制药因有价格涨跌幅限制的日收盘价格涨幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘,益佰制药报收于4.36元,上涨10.1%,换手率11.75%,成交量93.06万手,成交额3.97亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600594","BK0039","BK0097","BK0096","BK0070","BK0188","BK0077","BK0060","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134773","title":"益佰制药(600594)披露获得注射用阿扎胞苷药品注册证书,3月30日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623134773?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:38","pubTimestamp":1774863525,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘,益佰制药报收于3.93元,较前一交易日上涨2.34%,最新总市值为31.12亿元。该股当日开盘3.83元,最高3.93元,最低3.82元,成交额达5461.37万元,换手率为1.77%。贵州益佰制药股份有限公司近日收到国家药品监督管理局核准签发的注射用阿扎胞苷《药品注册证书》,药品批准文号为国药准字H20263700,注册分类为化学药品4类,视同通过仿制药一致性评价。截至2024年12月31日,累计研发投入1,893.41万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600594","BK0028","BK0070","BK0012","BK0077","BK0097","BK0039","BK0188","BK0239","BK0096","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622519823","title":"益佰制药最新公告:获得注射用阿扎胞苷药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622519823","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622519823?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:01","pubTimestamp":1774609305,"startTime":"0","endTime":"0","summary":"益佰制药(600594.SH)公告称,公司近日收到国家药监局核准签发的注射用阿扎胞苷《药品注册证书》。该药品为化学药品4类,适用于治疗中危-2及高危骨髓增生异常综合征、慢性粒-单核细胞白血病及特定急性髓系白血病患者。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700041114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600594","BK0039","BK0096","BK0028","BK0070","BK0097","BK0012","BK0060","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778171516715,"stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.1876},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0579},{"period":"1year","weight":0.112},{"period":"ytd","weight":0.0226}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0745},{"period":"3month","weight":0.0282},{"period":"6month","weight":0.0457},{"period":"1year","weight":0.2505},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州益佰制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45929人(较上一季度减少5.97%)","perCapita":"17242股","listingDate":"2004-03-23","address":"贵州省贵阳市云岩区白云大道220-1号","registeredCapital":"79192万元","survey":" 贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售,综合性医院、肿瘤专科医院、肿瘤放疗中心的运营与管理,开发、研制、生产及销售以苗药为特色的大健康产品。公司的主要产品是注射用洛铂、银杏达莫注射液、抗肿瘤类、心脑血管类、男科类、妇科类、其他、注射用瑞替普酶、科博肽、医疗服务、糖果、植物饮料、膏滋。","listedPrice":14.4},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益佰制药,600594,益佰制药股票,益佰制药股票老虎,益佰制药股票老虎国际,益佰制药行情,益佰制药股票行情,益佰制药股价,益佰制药股市,益佰制药股票价格,益佰制药股票交易,益佰制药股票购买,益佰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}